Patent · US Active

Method for killing IL-1 alpha expressing cells

US8784817B2 · kind B2 · utility

7Cited by
1References
2Claims
0Family size

Assignee

Inventor

Key dates

Filing dateFeb 14, 2013
Grant dateJul 22, 2014
Priority date—
Expiry dateFeb 14, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/545
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.